DXCM
T3DexCom, Inc.
OverviewDexCom, Inc. is a medical technology company that develops and markets continuous glucose monitoring (CGM) systems, including G6 and G7, for individuals managin
DexCom, Inc. is a medical technology company that develops and markets continuous glucose monitoring (CGM) systems, including G6 and G7, for individuals managing diabetes. Their products provide real-time glucose data, aiming to supersede traditional finger-prick tests. They sell to healthcare professionals and directly to patients, expanding coverage for type 2 non-insulin users and exploring prediabetes screening. The company recently acquired Nutrisense for nutrition insights.
Search Keywords Brand Product
- Continuous Glucose Monitoring
- CGM
- Dexcom G7
- Dexcom G6
- Dexcom ONE
- Stello app
- Dexcom Smart Basal
- DexCom Flex
- Dexcom Share
- diabetes management
- prediabetes screening
- metabolic health
- glucose sensing solution
- wearable health devices
- digital health platforms
- AI-powered insights
- insulin management
Search Keywords Event Phrases
- DexCom earnings
- ADA Scientific Sessions
- DexCom Investor Day
Search Keywords Policy Regulatory
- CMS reimbursement
- Type 2 non-insulin coverage
- FDA Tempo pilot
- Medicare Advantage CGM coverage
- What They Do (Plain English & Analogies)
- DexCom is like a personal glucose radar for people with diabetes. Instead of pricking your finger multiple times a day to check blood sugar, DexCom provides a small, wearable sensor that continuously measures glucose levels just under the skin. This data is sent wirelessly to a smartphone or a dedicated receiver, giving users real-time updates on their sugar trends. It's like having a constant dashboard for your glucose, showing you if it's going up, down, or staying steady, which helps people manage their diabetes more effectively, make better decisions about food and exercise, and even prevent dangerous highs or lows. They are also expanding this 'glucose radar' concept to help people with prediabetes understand their metabolic health better.
- Very Brief History
- Founded in 1999, DexCom, Inc. has grown into a leading medical technology company specializing in continuous glucose monitoring (CGM) systems. Key milestones include the development and marketing of its G-series CGM systems, such as the G6, and the ongoing rollout of its next-generation G7 system. The company has also expanded its offerings with products like Dexcom ONE and Stello, and recently acquired Nutrisense in Q2 2026 to enhance nutrition-focused insights. DexCom has been instrumental in advocating for broader reimbursement for CGM technology, particularly for non-insulin-using Type 2 diabetes patients.
- "Street Stereotype"
- DexCom is generally perceived by investors and analysts as a high-growth MedTech company, a leader in the wearable health space, particularly in Continuous Glucose Monitoring (CGM). The 'street' sees it benefiting significantly from expanding reimbursement for chronic disease monitoring, driven by policy favoring preventative care and AI-enhanced platforms. There's a strong focus on its ability to expand market access beyond insulin-dependent users to the much larger Type 2 non-insulin population and even prediabetes. However, it also faces scrutiny regarding its valuation multiples and the potential substitution risk from GLP-1 weight-loss drugs, which could moderate demand for diabetes management tools.
- Subsidiaries On Linked In*
- Nutrisense — Acquired in Q2 2026, focuses on nutrition-focused insights based on CGM data.; LinkedIn: nutrisense
- Customer Sectors & Example Clients
- DexCom's customers primarily include individuals managing diabetes (Type 1, Type 2 intensive, Type 2 basal, and increasingly Type 2 non-insulin) and healthcare practitioners such as endocrinologists, physicians, and diabetes educators. The company also works with commercial payers and Pharmacy Benefit Managers (PBMs) to secure reimbursement. An example collaborator mentioned in the transcript is CVS Health, with whom they published a real-world evidence study for non-insulin Type 2 customers. While specific client companies (beyond CVS Health as a collaborator) are not named in the transcript, their commercial payers would include major health insurance providers and PBMs in the US and internationally.
- New Customers / Segments They'Re Targeting
- DexCom is aggressively targeting new customer segments, most notably the 25 million people in the U.S. with Type 2 diabetes who are not currently using insulin. They are also looking to expand into the prediabetes market, aiming to help screen the 115 million Americans with prediabetes and guide them towards better metabolic health. This expansion is supported by clinical trials like CONNECT for Type 2 non-insulin users and participation in the FDA's Tempo digital device pilot for prediabetes screening.
- Supply Chain And Sourcing Geographies
- DexCom's supply chain involves manufacturing facilities in the United States, specifically in Mesa, Arizona. The company is also making significant investments in expanding its manufacturing footprint internationally, with a new factory in Ireland preparing for commercial production later in 2026. This indicates a strategy to diversify and strengthen its global manufacturing and supply chain capabilities. The transcript highlights ongoing efforts in manufacturing efficiencies and quality management.
- Sales Geographies And Expansion Plans
- DexCom currently sells its products across the United States and various international markets. Specific international markets highlighted for strong performance and access expansion include France, Canada, and Germany (with the launch of DexCom Flex). The company has plans to expand the availability of its G7 15-day system across its international markets as quickly as possible, following its recent clearance in Health Canada. They are also continuing to work on expanding Type 1 diabetes coverage in several of their top 10 international markets, indicating ongoing growth opportunities outside the U.S.
- How Key Themes May Help/Hurt
- The 'MedTech Long '25: Wearable Health' theme significantly helps DexCom. Expanding reimbursement for remote monitoring and CGM technologies by CMS and Medicare Advantage directly broadens DexCom's market access and utilization, especially for the large Type 2 non-insulin population. Policy tailwinds favoring preventative technology and continuous monitoring align perfectly with DexCom's strategy to screen for prediabetes and improve metabolic health. The adoption of AI-enhanced wearable platforms, as seen in their redesigned Stello app and future G8 capabilities, improves diagnostic and proactive care, strengthening their competitive position. However, the theme also highlights a potential hurt: the GLP-1 substitution risk. As obesity and diabetes rates potentially decline due to GLP-1 medications, demand for CGMs could moderate, impacting a key market segment. Additionally, high valuation multiples for wearable health names make them vulnerable to macro-economic shifts or any disappointments in growth.
3 Main Long-Term Bull Details
- Expanding Market Access: DexCom is poised for significant growth by expanding CGM coverage to the vast Type 2 non-insulin population in the U.S. (25 million people) and internationally, backed by strong clinical evidence from trials like CONNECT and ongoing advocacy with CMS and commercial payers.
- Product Innovation and Pipeline: The company has a robust product roadmap, including the successful rollout of the G7 15-day system with improved customer satisfaction, the development of Smart Basal for simplified insulin management, and the highly anticipated G8 system, which promises step-change improvements in accuracy, size, and multi-analyte capabilities, extending beyond glucose monitoring.
- Metabolic Health Expansion: DexCom is strategically moving beyond diabetes management into diabetes prevention and broader metabolic health, exemplified by its participation in the FDA's Tempo pilot to screen for prediabetes and the acquisition of Nutrisense to provide nutrition-focused insights, opening up a massive new market opportunity.
3 Main Long-Term Bear Details
- GLP-1 Substitution Risk: The continued rapid adoption and expansion of GLP-1 therapies pose a significant substitution risk for continuous glucose monitoring (CGM) demand, especially for Type 2 diabetes management.
- Reimbursement Delays and Complexity: While progress is being made, delays or restrictive conditions in securing broad reimbursement for Type 2 non-insulin and prediabetes populations, especially from government payers like CMS, could slow market penetration and adoption.
- Intense Competition and Pricing Pressure: The CGM market is highly competitive, with established players and new entrants. This competition could lead to pricing pressure, increased R&D costs, and challenges in maintaining market share, particularly as technology advances and commoditization risks emerge.
- Competitors And Differentiation
- DexCom's primary competitors in the continuous glucose monitoring (CGM) market include Abbott (with its FreeStyle Libre system), Medtronic, and Senseonics. DexCom differentiates itself through several key aspects: superior product performance (accuracy, reliability, extended wear time with G7 15-day), a focus on an excellent customer experience (evidenced by increasing G7 Net Promoter Scores and the redesigned Stello app with AI-driven insights), and aggressive efforts to expand reimbursement and market access, particularly for the Type 2 non-insulin population. Their upcoming G8 system promises further step-change improvements in accuracy, reliability, and a smaller form factor, along with multi-analyte capabilities, aiming to set a new standard in the market.
- Recent Performance & What The Market'S Focused On
- DexCom reported a strong second quarter of 2026, with worldwide revenue growth of 13% (12% organic) to $1.31 billion, driven by solid demand, broader access, and share gains globally. The company raised its full-year revenue guidance to $5.18 billion to $5.25 billion and increased its non-GAAP gross profit, operating profit, and adjusted EBITDA margin guidance, reflecting excellent execution and cost discipline. New customer starts remained strong, with a sequential uptick in the U.S. The market is heavily focused on the progress towards full coverage for Type 2 diabetes patients not using insulin, especially the CMS decision expected by year-end 2026 for a mid-2027 effective date, the successful rollout and adoption of the G7 15-day system, and the potential of the FDA's Tempo pilot to unlock the prediabetes market. The $1 billion share repurchase authorization, with $600 million executed in Q2, also signals financial strength and commitment to shareholder returns.
- Revenue Segments And Estimated Mix
- U.S. Revenue — Mix: ~71.2%; Source: Q2 2026 transcript ($933M out of $1.31B total); Trend: Increased 11% YoY
- International Revenue — Mix: ~28.8%; Source: Q2 2026 transcript ($375M out of $1.31B total); Trend: Grew 19% YoY (16% organic)
- Product Brands
- DexCom G6
- Dexcom Real-Time API
- Dexcom ONE
- Dexcom Share
- Dexcom G7
- Stello
- DexCom Flex
- Dexcom Smart Basal
Bull / Bear DetailsDexCom is a compelling long opportunity as of 2026-08-07, driven by expanding CGM reimbursement for Type 2 non-insulin patients, validated by strong Connect tri
Thesis
DexCom is a compelling long opportunity as of 2026-08-07, driven by expanding CGM reimbursement for Type 2 non-insulin patients, validated by strong Connect trial data and commercial coverage. Continued product innovation with G7 15-day and G8, coupled with strategic acquisitions like Nutrisense and the Tempo pilot for prediabetes, broadens market reach. Strong financial performance and operational execution underpin the bullish case, despite ongoing GLP-1 substitution risks and initial costs from new factory ramp-ups.
Bull case
DexCom is significantly expanding its addressable market through robust reimbursement efforts. The Connect trial demonstrated a 1.6% A1C improvement and 97% median wear for Type 2 non-insulin users, strengthening the case for broad coverage. Commercial payers now cover over 7 million Type 2 non-insulin lives, and CMS coverage is anticipated by mid-2027, unlocking a massive Medicare population.
Product innovation and global expansion are key growth drivers. The G7 15-day system is on track for nearly 50% U.S. customer conversion by year-end 2026 and is rolling out internationally, including Canada. The upcoming G8 sensor promises step-change improvements in accuracy, a smaller form factor, and multi-analyte capabilities. The FDA's Tempo pilot for prediabetes screening further expands future market opportunities.
Enhanced customer experience and strong financial performance bolster the investment case. The redesigned Stello app offers AI-driven insights and improved food logging, complemented by the Nutrisense acquisition for personalized nutrition coaching. DexCom reported 13% Q2 2026 revenue growth, a 400 basis point gross margin improvement, and raised full-year guidance, alongside a $1 billion share repurchase authorization.
Bear case
The rapid adoption and expansion of GLP-1 therapies pose a potential substitution risk for CGM demand, particularly in Type 2 diabetes management. While DexCom's Connect trial suggests a complementary relationship, with the largest A1C improvement seen in GLP-1 users, the long-term impact on overall CGM market size and growth rates remains a concern.
Despite significant progress, reimbursement processes for new indications and technologies can still lag, potentially slowing adoption. While CMS coverage for Type 2 non-insulin is expected, the mid-2027 timeline means a delay, and there's ongoing work to eliminate hurdles like prior authorizations. Any unexpected restrictive coverage requirements could temper market penetration.
DexCom's valuation multiples remain high, making the stock vulnerable to broader macroeconomic shifts, interest rate changes, or any disappointments in utilization or growth. Additionally, the ramp-up of the new Ireland manufacturing facility will incur initial costs, potentially impacting gross margins in the short term before efficiencies are fully realized.
Bull / Bear Case
- Bear Case
- The rapid adoption and expansion of GLP-1 therapies present a potential substitution risk for CGM demand, particularly in Type 2 diabetes management, despite DexCom's data suggesting a complementary relationship. While progress is being made, reimbursement processes for new indications and technologies can still face delays or restrictive conditions, potentially slowing market penetration, especially for the anticipated CMS coverage for Type 2 non-insulin patients by mid-2027. DexCom's valuation multiples, while lower than historical highs, remain elevated compared to some industry peers, making the stock vulnerable to broader macroeconomic shifts, interest rate changes, or any disappointments in utilization or growth. Additionally, the ramp-up of the new Ireland manufacturing facility will incur initial costs, which could temporarily impact gross margins before efficiencies are fully realized.
- Bull Case
- DexCom is poised for significant growth driven by expanding market access, particularly in the Type 2 non-insulin diabetes population. The Connect trial demonstrated a 1.6% A1C improvement and 97% median wear for these users, strengthening the case for broad commercial and anticipated CMS coverage by mid-2027, unlocking a massive addressable market. Product innovation, including the successful G7 15-day system rollout (targeting 50% U.S. conversion by year-end 2026) and the upcoming G8 sensor with enhanced accuracy and multi-analyte capabilities, further fuels growth. Strategic initiatives like the FDA's Tempo pilot for prediabetes screening and the Nutrisense acquisition for personalized nutrition insights broaden future market opportunities. Strong Q2 2026 financial performance, including 13% revenue growth, 400 basis point gross margin improvement, raised full-year guidance, and a $1 billion share repurchase authorization, underscores operational excellence and profitability.
- More Compelling & Why
- Bull. DexCom's current P/E ratio of approximately 34.5x is significantly below its 5-year median of 91.5x, suggesting a more reasonable valuation after a prior de-rating. The strongest argument for the bull case is the substantial and expanding market opportunity in Type 2 non-insulin diabetes, validated by the Connect trial and growing commercial coverage, alongside the potential for prediabetes screening. A significant slowdown in new customer starts or a more pronounced negative impact from GLP-1 therapies on CGM adoption than currently anticipated, leading to a downward revision of long-term growth forecasts and further margin pressure, would flip my view to bearish.
Key Factors
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| FDA Tempo Digital Device Pilot Progress for Prediabetes Screening | Success in the Tempo pilot could pave the way for FDA clearance for prediabetes screening, unlocking a massive new market of 115 million Americans with prediabetes and expanding Dexcom's role in preventative health. | Any public announcements from Dexcom or the FDA regarding milestones, preliminary findings, or next steps in the Tempo pilot program, which began enrolling its first cohort in July 2026. | Bullish if the pilot demonstrates positive results for prediabetes screening and leads to a clear regulatory pathway for a prediabetes label. | Dexcom press releases, FDA announcements, investor presentations. | Google News alerts for 'Dexcom Tempo pilot', 'FDA prediabetes CGM'. | N/A |
| G7 15-day System U.S. Conversion Rate & International Rollout | Higher conversion to the 15-day system improves customer satisfaction, potentially reduces churn, and contributes to gross margin expansion due to manufacturing efficiencies. International launches open new growth avenues. | Dexcom's updates on the U.S. customer conversion rate towards the 50% year-end 2026 target. Specific announcements of G7 15-day launch dates in Canada (expected H2 2026) and other international markets. | Bullish if U.S. conversion rate is on track or exceeds 50% by year-end 2026, and if international launches proceed as scheduled or faster. | Dexcom earnings calls, investor presentations, company press releases. | Reddit communities (e.g., r/diabetes, r/cgm) for user feedback on G7 15-day adoption and satisfaction. | IQVIA DeviceTrack: Dexcom G7 15-day prescription volume growth. |
| Global New Customer Starts & U.S. Sequential Growth | New customer acquisition is a primary driver of revenue growth and indicates successful market penetration and competitive share gains. Sustained growth demonstrates strong demand for Dexcom's CGM products. | Commentary on new patient starts during the next earnings call (Q3 2026), looking for sustained sequential growth in the U.S. and global new customer starts remaining at or above record levels. | Bullish if global new customer starts continue to be in line with or exceed previous record quarters, and if the U.S. shows continued sequential growth. | Dexcom earnings calls and investor presentations (Q3 2026 earnings call expected late October/early November 2026). | Google Trends: 'Dexcom CGM' search interest, 'continuous glucose monitor' search interest. | IQVIA DeviceTrack: Dexcom new patient prescriptions. |
| Full-Year Gross and Operating Margin Guidance Achievement | Achievement of raised margin guidance indicates improved operational efficiency, favorable product mix (G7 15-day), and effective cost management, directly impacting profitability and cash flow. | Actual reported non-GAAP gross profit margin (guidance: approx. 64%) and operating profit margin (guidance: 23.5% to 24%) in Q3 and Q4 2026 earnings reports. Monitor for commentary on Ireland factory ramp-up impact. | Bullish if reported margins meet or exceed the raised guidance, indicating strong execution and underlying profitability trends. | Dexcom earnings releases and investor presentations (Q3 2026 earnings call expected late October/early November 2026). | N/A | N/A |
| CMS Coverage Decision for Type 2 Non-Insulin Diabetes | This decision would significantly expand Dexcom's addressable market in the U.S. by including approximately 25 million Type 2 non-insulin patients, driving substantial long-term revenue growth and solidifying CGM as a standard of care. | Official announcement from CMS regarding the coverage decision for CGM in Type 2 non-insulin patients. Dexcom expects a decision before the end of 2026, with an anticipated effective date of mid-2027. | Bullish if CMS announces broad coverage for Type 2 non-insulin patients, especially without restrictive A1C thresholds or other significant limitations. | CMS official announcements, Dexcom investor relations press releases, SEC filings (10-Q, 8-K). | Google News alerts for 'CMS CGM Type 2 non-insulin coverage', 'Medicare diabetes technology'. | N/A |
Key Reported Metrics, Reratings Triggers & ResultsThis highlights the success of DexCom's international expansion strategy, driven by expanded access and product portfolio, which is a key growth pillar for the
Upcoming print · 2026-10-29
| Key reported metrics | ||
|---|---|---|
| Metric | Last period | Why it matters |
| International Organic Revenue Growth | 16% | This highlights the success of DexCom's international expansion strategy, driven by expanded access and product portfolio, which is a key growth pillar for the company. |
| Non-GAAP Gross Profit Margin (YoY Growth) | 6.7% | Gross margin indicates manufacturing efficiencies, product mix (G7 15-day), and pricing power. Sustained improvement signals strong operational execution and profitability, impacting overall earnings. |
Key QuestionsWill CMS announce a broad and favorable coverage decision for CGM in Type 2 non-insulin patients by the end of 2026, and will the market's reaction to this anno
Will CMS announce a broad and favorable coverage decision for CGM in Type 2 non-insulin patients by the end of 2026, and will the market's reaction to this announcement align with Dexcom's mid-2027 implementation expectations?
- Question 2
Can Dexcom maintain its strong gross and operating margin performance in Q3 2026, given the anticipated increased investment and hiring for the Ireland manufacturing facility, while continuing the G7 15-day system conversion?
- Question 3
Will the continued rapid adoption and new launches of GLP-1 therapies, as reported in Q3/Q4 2026 earnings, pose a greater-than-expected substitution risk for CGM demand, or will Dexcom's Connect trial data continue to demonstrate a complementary relationship, influencing new patient starts?
Earnings Transcript Summary
· 2026Q2 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 1. **Expanding access and market share for CGM globally**: Management is focused on achieving full coverage for all people with diabetes, particularly the 25 million people in the U.S. with type 2 diabetes not using insulin, through initiatives like the 'Road to 100' and leveraging the strong Connect trial results. They also aim to expand international market share through access efforts and product portfolio expansion. 2. **Product innovation and enhancing customer experience**: This includes the continued rollout of the G7 15-day system, the launch of the redesigned Stello app with new AI-driven insights and enhanced food logging, and the advancement of their technology roadmap with products like Dexcom Smart Basal and the G8 sensor. 3. **Sustaining strong financial performance and strategic capital allocation**: Management highlighted robust revenue growth, excellent gross and operating margin execution, significant free cash flow generation, and the execution of a $1 billion share repurchase authorization in 2026. They also mentioned the acquisition of Nutrisense to enhance customer experience and provide personalized insights. | The call conveyed a highly positive and confident tone, reflecting DexCom's strong operational execution and financial performance in Q2 2026. The key takeaway was the company's robust revenue growth, significant margin expansion, and record new customer starts globally. Management expressed strong optimism about future growth drivers, particularly the compelling Connect trial results for Type 2 non-insulin patients, the successful rollout and positive customer feedback for the G7 15-day system, and strategic initiatives like the Nutrisense acquisition and the G8 development. The company also raised its full-year guidance for gross profit, operating profit, and adjusted EBITDA margins, reinforcing a positive outlook despite anticipated foreign exchange headwinds. | For the first quarter of 2026, worldwide revenue grew 15% on a reported basis and 12% on an organic basis. U.S. revenue increased 11%. International revenue grew 26% on a reported basis and 17% on an organic basis. | 1. **Connect trial results and CMS coverage for Type 2 non-insulin patients**: Analysts questioned the reception of the Connect data among doctors and the timeline for Medicare reimbursement for Type 2 non-insulin users. Management responded that the Connect trial showed significant A1C improvement (1.6% A1C improvement, 0.9% difference vs. control) and high engagement (97% median wear), which are even better than previous landmark studies and strengthen the case for reimbursement. They have submitted the data to CMS, expect a decision before year-end, and anticipate coverage to take effect mid-2027. They also clarified that A1C thresholds for coverage are inconsistent with their discussions and existing broad commercial coverage. 2. **U.S. CGM growth sustainability and new patient starts**: Analysts inquired about the confidence in sustaining double-digit growth in the U.S. and the drivers of new patient additions. Management stated that Q2 new patient starts were in line with the record from Q1 globally, with a sequential uptick in the U.S., driven by broad-based performance across all patient segments. They highlighted the 9 million people in the U.S. with coverage but not yet using CGM, and the positive impact of G7 15-day improvements and expanding coverage. 3. **G7 15-day system conversion and its margin impact**: Analysts asked for an update on the conversion rate to the 15-day system in the U.S. and its accretive margin impact. Management confirmed that the transition is progressing in line with expectations, with the G7 15-day system now accessible for all adult G7 customers in the U.S. following Tandem pump integration. They remain on track to convert nearly 50% of the U.S. customer base by year-end, noting that while it contributed to margins in Q2, the more significant margin impact will be seen in 2027 as the starting base for the year will be much higher. | Worldwide revenue grew 13% on a reported basis and 12% on an organic basis compared to the second quarter of 2025. U.S. revenue increased 11% compared to the second quarter of 2025. International revenue grew 19% on a reported basis and 16% on an organic basis for the second quarter. |
Transcript Tidbits
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| DexCom reported solid demand for CGM globally, benefiting from broader access and share gains across several core markets and patient categories. The company is pursuing full coverage for the 25 million people in the U.S. with type 2 diabetes not using insulin, an initiative called 'Road to 100' to achieve coverage for all people with diabetes. Commercial coverage now exists for all people with diabetes across the four largest commercial PBMs, representing reimbursement for over 7 million type 2 non-insulin users. The Connect trial, a randomized control trial for type 2 non-insulin users, showed a 1.6% A1C improvement for the Dexcom CGM group, leading to a 0.9% difference compared to the control group, with median wear of 97% over 26 weeks. DexCom has submitted this data to CMS to support non-insulin coverage expansion, expecting a decision before the end of this year, with implementation planned for mid-2027. The FDA also selected Dexcom as the first company for the Tempo digital device pilot, aiming to demonstrate CGM's ability to screen for prediabetes among 115 million Americans. Internationally, revenue grew 19% (16% organic), driven by expanded access in markets like France and Canada. The company sees a significant opportunity to help millions more globally, with over 60 million potential lives in core international markets (T1, Basal, NIT) yet to be impacted. DexCom Flex, a 15-day sensor, was launched in Germany to address type 2 basal and non-insulin markets in select geographies. | The company noted 'share gains across several core markets' and 'some share taking across those' in the U.S. market, indicating ongoing competitive dynamics. However, no specific competitors were mentioned by name. | The administration is committed to reducing the burden of chronic disease and expanding access to new technologies, evidenced by the FDA's Tempo digital device pilot. The Connect study results are expected to further evolve ADA standards of care, recommending CGM for all people with diabetes. The industry is also anticipating CMS's new 'Software as a Medical Service' payment framework for algorithm-driven technologies in CY 2027 and updates to remote patient monitoring (RPM) and remote therapeutic monitoring (RTM) reimbursement policies. The rapid adoption of GLP-1 therapies poses a potential substitution risk for CGM demand, though Dexcom's Connect trial data suggests a complementary relationship between CGM and incretin therapy. | DexCom's CEO, Jake Leach, reiterated three priorities: being the premier glucose sensing solution for all, setting the standard for customer experience, and expanding international market share. The company laid out new 5-year financial targets, including a $1 billion share repurchase authorization for 2026. DexCom plans to educate the market on Connect trial outcomes globally to drive reimbursement. The company believes its opportunity extends beyond diabetes treatment to diabetes prevention, aiming to use CGM for prediabetes screening. The technology roadmap includes the fully redesigned Stello app with AI-driven insights and enhanced food logging, which will serve as the foundation for the G Series app's evolution. Dexcom Smart Basal, a personalized dosing module, is in a pilot program and shows potential to become the new standard of care for basal insulin management. The G7 15-day system is on track to convert nearly 50% of the U.S. customer base by year-end and will launch in Canada in H2 2026, followed by other international markets. The G8 sensor is on track for late 2027/early 2028 launch, promising step-change improvements in accuracy, reliability, and a smaller wearable size, with future plans for multi-analyte capabilities (ketones, potassium). The company raised its full-year 2026 revenue guidance to $5.18 billion to $5.25 billion (11-13% growth), non-GAAP gross profit margin to approximately 64%, non-GAAP operating profit margin to 23.5-24%, and adjusted EBITDA margin to 31.5-32%. | Wearable | AI-driven insights/Personalized Health: The Stello app's 'AI driven insights' and the Nutrisense acquisition for 'personalized nutrition coaching based on CGM' highlight a growing trend towards leveraging artificial intelligence for individualized health management. Preventative Health/Early Screening: Dexcom's participation in the Tempo pilot to screen for prediabetes and its stated goal to move 'beyond diabetes care and into diabetes prevention' signifies a broader industry shift towards early intervention and preventative health strategies. Multi-analyte platforms: The development of the G8 as a 'multi-analyte platform' for substances like ketones and potassium suggests an emerging trend in wearable diagnostics to monitor a wider range of biomarkers beyond glucose. | Today, we reported second quarter revenue growth of 13% compared to the second quarter of 25. global new customer starts remained in line with our previous record from last quarter. Over the 6-month study period, we saw a 1.6% A1C improvement for the Dexcom CGM group. Smart Basal has helped customers reach an optimal basal dose in only 3 weeks on average. With g 7 net promoter scores increasing in each of the last 3 quarters. We are raising the midpoint of our guidance with an updated range of $5.18 billion to $5.25 billion. Our cash flow generation continues to be a key differentiator. | The comps get a little tougher because we had some great access wins in the back half of last year. We have to be mindful of, obviously, letting them know that the CMS coverage does not exist today. We expect that to have about a $15 million impact to international revenue in the second half of the year relative to our prior guidance. The Q4 and the Q3, Q4 comps, especially Q3 got a little bit tougher in the international business. | The company is expanding its investment in Ireland to prepare for commercial production later this year. This includes 'quite a bit of hiring in Ireland here into the third quarter' for manufacturing roles, with these new hires initially focused on training before production begins. |
Upcoming Events
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| DXCM_80554779 | Final rule publication in November 2026; effective January 1, 2027. | 2026-11-01 | 2027-01-01 | CMS to publish the CY 2027 Physician Fee Schedule final rule, finalizing changes to remote patient monitoring (RPM) and remote therapeutic monitoring (RTM) reimbursement policies. | This rule could significantly alter the operational and financial models for companies providing remote monitoring solutions, directly impacting the reimbursement landscape for wearable health devices including Dexcom's offerings. | Theme | 2026-07-30 | earnings_transcript |
| DXCM_e0606eaf | before the end of this year | 2026-08-07 | 2026-12-31 | CMS decision on coverage expansion for Type 2 non-insulin diabetes patients, following the submission of Connect trial data. | This decision has the potential to significantly expand the addressable market for Dexcom CGM in the US, impacting 25 million Type 2 non-insulin customers. | Ticker | 2026-07-30 | earnings_transcript |
| DXCM_b887655c | by year end | 2026-10-01 | 2026-12-31 | Dexcom expects to convert nearly 50% of its US customer base to the G7 15-day system. | This conversion is translating into stronger customer satisfaction and is expected to contribute to improved gross margins. | Ticker | 2026-07-30 | earnings_transcript |